Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
- 30 October 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Genetics
- Vol. 37 (12), 1315-1316
- https://doi.org/10.1038/ng1671
Abstract
Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific secondary somatic mutation, EGFR T790M. Here we describe a family with multiple cases of non-small cell lung cancer associated with germline transmission of this mutation. Four of six tumors analyzed showed a secondary somatic activating EGFR mutation, arising in cis with the germline EGFR mutation T790M. These observations implicate altered EGFR signaling in genetic susceptibility to lung cancer.Keywords
This publication has 15 references indexed in Scilit:
- Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProceedings of the National Academy of Sciences of the United States of America, 2005
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- Strategies to overcome resistance to targeted protein kinase inhibitorsNature Reviews Drug Discovery, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic PathwaysScience, 2004
- The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinaseBiochemical and Biophysical Research Communications, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003